Juvaris BioTherapeutics Announces Progress in Alliance with Bayer Animal Health
Burlingame, CA – January 9, 2009
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced the achievement of a milestone event in its licensing agreement with Bayer HealthCare’s Animal Health Division for the evaluation of Juvaris’ technology for applications in animal health markets.
Bayer Animal Health has completed the first evaluation period examining the Juvaris cationic lipid-DNA technology in multiple disease settings in animal health including proof of concept in important food producing animal species. Based on the results of these studies Bayer will be advancing these research efforts.
"We are pleased with the continued progress of Bayer Animal Health in evaluating the Juvaris technology as a platform for the development of a range of products to serve the field of animal health," said Grant E. Pickering, President and CEO of Juvaris. "The results demonstrated to date indicate the broad applicability of our technology and serve as further validation of Juvaris’ immunotherapeutics to address unmet needs in healthcare."
In commenting on the milestone event Professor Norbert Schmeer, Head of Clinical Research and Development at Bayer Animal Health, said “The Juvaris technology in combination with our in-house expertise dramatically expands our ability to develop new and innovative products that promote immune stimulation and disease prevention in several species for numerous indications.”
Juvaris and Bayer entered into the worldwide licensing agreement in February 2008 to evaluate and execute programs directed at immune stimulation and disease prevention in a variety of animal species. The agreement anticipates that Bayer Animal Health will continue to financially support Juvaris' research, product formulation, development and GMP manufacturing activities to support its alliance obligations. In return Bayer Animal Health will have complete access to the Juvaris immunotherapy and vaccine technology in the field of animal health.
Juvaris BioTherapeutics is a clinical stage company developing adjuvanted vaccines and immunotherapeutics to treat infectious diseases and cancer. The Company’s lead product candidate, JVRS-100, is currently in clinical development as an adjuvant to improve the efficacy of seasonal influenza vaccines in the elderly population. The Company is also developing proprietary vaccines for HSV-2, universal flu and pandemic flu and is initiating clinical development of an immunotherapeutic to treat acute leukemia with grant funding from a leading academic institution. Juvaris completed a Series A financing led by Kleiner Perkins Caufield & Byers and has been awarded multiple NIH grants. More information about the Company and its technology can be obtained at its website: www.juvaris.com.
About Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading innovative companies in the health care and medical products industry. The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The company's pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.
With sales of EUR 956 million (2007), the Animal Health Division is one of the world’s leading manufacturers of veterinary drugs. The division manufactures and markets approximately 100 different veterinary drugs and care products for food-supplying animals and companion animals.
Grant E. Pickering
Juvaris BioTherapeutics, Inc.
863A Mitten Road
650-259-1800 ext. 227